Multiple System Atrophy (MSA) Therapeutics Market

Future Market Insights

Key Insight

The multiple system atrophy (msa) therapeutics market is projected to grow from USD 149.6 million in 2025 to USD 230.2 million by 2035, at a CAGR of 4.4%. Parkinsonian will dominate with a 63.7% market share, while magnetic resonance imaging (mri) will lead the diagnosis segment with a 41.5% share.

August 23, 2025

Anurag Sharma

299 Pages

Cite this Report

Multiple System Atrophy (MSA) Therapeutics Market

https://www.futuremarketinsights.com/reports/multiple-system-atrophy-msa-therapeutics-market

License

Buy Now

Summary ToC Companies

Key Players

BlackRock
Neuropore Therapies Inc
Newron Pharmaceuticals SpA
ProMIS Neurosciences Inc
Stealth BioTherapeutics Corp
Sumitomo Dainippon Pharma Co. Ltd

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Multiple System Atrophy (MSA) Therapeutics Market

Key Players

Similar Industry Reports